- Home
- PEN vs CYTK Comparison
PEN vs CYTK Comparison
Compare PEN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- CYTK
- Stock Information
- Founded
- PEN 2004
- CYTK 1997
- Country
- PEN United States
- CYTK United States
- Employees
- PEN N/A
- CYTK N/A
- Industry
- PEN Medical/Dental Instruments
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- CYTK Health Care
- Exchange
- PEN Nasdaq
- CYTK Nasdaq
- Market Cap
- PEN 9.1B
- CYTK 5.7B
- IPO Year
- PEN 2015
- CYTK 2004
- Fundamental
- Price
- PEN $241.10
- CYTK $48.38
- Analyst Decision
- PEN Buy
- CYTK Buy
- Analyst Count
- PEN 15
- CYTK 16
- Target Price
- PEN $259.86
- CYTK $84.07
- AVG Volume (30 Days)
- PEN 316.9K
- CYTK 1.1M
- Earning Date
- PEN 02-20-2025
- CYTK 02-25-2025
- Dividend Yield
- PEN N/A
- CYTK N/A
- EPS Growth
- PEN N/A
- CYTK N/A
- EPS
- PEN 0.89
- CYTK N/A
- Revenue
- PEN $1,163,776,000.00
- CYTK $3,219,000.00
- Revenue This Year
- PEN $13.55
- CYTK N/A
- Revenue Next Year
- PEN $14.48
- CYTK $706.87
- P/E Ratio
- PEN $268.19
- CYTK N/A
- Revenue Growth
- PEN 16.96
- CYTK N/A
- 52 Week Low
- PEN $148.00
- CYTK $45.66
- 52 Week High
- PEN $277.34
- CYTK $110.25
- Technical
- Relative Strength Index (RSI)
- PEN 52.20
- CYTK 45.47
- Support Level
- PEN $234.55
- CYTK $46.52
- Resistance Level
- PEN $241.89
- CYTK $50.32
- Average True Range (ATR)
- PEN 6.40
- CYTK 1.67
- MACD
- PEN -1.31
- CYTK 0.04
- Stochastic Oscillator
- PEN 36.55
- CYTK 54.08
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.